DMX-200 Kidney Disease Study Reached Milestone
Patients with focal segmental glomerulosclerosis have now completed two years of long-term DMX-200 treatment.
Updated on Oct. 5, 2026 in Diabetes
Live Poll
Should patients have guaranteed access to experimental drugs after clinical trials conclude?
A patient has reached the two-year mark in an open-label extension study evaluating DMX-200 for focal segmental glomerulosclerosis. More than 90% of eligible participants from the global ACTION3 trial have transitioned into this long-term extension phase.
Why it matters
This extension study is critical for generating long-term safety and efficacy profiles for DMX-200, an experimental treatment for a rare kidney disease. These findings are essential for understanding how the drug performs beyond the initial randomized trial period.
In this ongoing open-label extension study, participants receive 120 milligrams of DMX-200 twice daily to monitor long-term outcomes. The study follows the 333-patient ACTION3 trial and includes data from 219 sites across 21 countries.
The players
Dimerix
A biopharmaceutical company focused on developing therapies for inflammatory diseases and kidney conditions like focal segmental glomerulosclerosis.
The details
DMX-200 is administered to patients after they have reached a stable dose of an angiotensin II receptor blocker. The treatment aims to address focal segmental glomerulosclerosis, a condition that damages the kidney's filtering units. By providing continued access to the medication, researchers can assess how sustained use of this 120-milligram twice-daily regimen impacts disease progression over time.
Timeline
March 2026: The final adult patient commenced treatment in the ACTION3 study.
October 2026: The first patient completed two years of the open-label extension study.
March 2027: The final adult patient is expected to complete the dosing period.
Health Landscape
This study is a critical component of the ongoing clinical pipeline for focal segmental glomerulosclerosis treatments. It follows the structural precedents set by the ACTION3 trial, which remains the primary reference point for assessing DMX-200.
Patients with kidney conditions should track the results of this trial as they emerge, as they may eventually inform new treatment options for glomerular diseases. Any changes to your current management plan should be discussed directly with your physician.
The takeaway
This study highlights the importance of long-term data in evaluating experimental kidney treatments. Patients should continue to follow guidance from their nephrologist regarding current standard therapies and remain aware of updates from clinical research trials.
What happens next
The final adult patient is expected to complete the required dosing period within 12 months of March 2026.
Further reading
For more information on current treatment paradigms, visit our Diabetes section.
Live Poll
Should patients have guaranteed access to experimental drugs after clinical trials conclude?
